Coverage
-
May 30, 2018
One investor backed by Glancy Prongay & Murray LLP is competing with another represented by Levi & Korsinsky LLP in separate bids filed in Massachusetts federal court Tuesday to be named lead plaintiff in a proposed class action accusing a bioscience company of withholding information about the toxicity of its signature muscular dystrophy treatment ahead of its initial public offering.
1 other articles on this case.
View all »